News
FDA approves Roche's "tumour agnostic" drug Rozlytrek
The FDA has approved Roche’s Rozlytrek (entrectinib), a so-called “tumour agnostic” drug that is approved to key into certain mutations in cancer, instead of where the disease originates. <
